Compare VRDN & KYIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRDN | KYIV |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United Arab Emirates |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | N/A | N/A |
| Metric | VRDN | KYIV |
|---|---|---|
| Price | $31.17 | $12.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $40.45 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | N/A |
| Earning Date | 11-05-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,789,000.00 | N/A |
| Revenue This Year | $26,257.62 | N/A |
| Revenue Next Year | $10.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23340.07 | N/A |
| 52 Week Low | $9.90 | N/A |
| 52 Week High | $34.04 | N/A |
| Indicator | VRDN | KYIV |
|---|---|---|
| Relative Strength Index (RSI) | 50.76 | N/A |
| Support Level | $30.57 | N/A |
| Resistance Level | $32.92 | N/A |
| Average True Range (ATR) | 0.98 | 0.00 |
| MACD | -0.39 | 0.00 |
| Stochastic Oscillator | 19.02 | 0.00 |
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Kyivstar Group Ltd is engaged in mobile communication.